Literature DB >> 6538408

Forskolin, a potent adenylate cyclase activator, lowers rabbit intraocular pressure.

B R Smith, R N Gaster, I H Leopold, L D Zeleznick.   

Abstract

To our knowledge, this is the first report of a topically applied, specific adenylate cyclase activator that reduces intraocular pressure. Forskolin, a novel adenylate cyclase activator, is reported to increase cyclic adenosine monophosphate (AMP) in intact cells. Cyclic AMP levels are increased with various antiglaucoma agents. Intraocular pressure in rabbits was significantly reduced with two concentrations of forskolin, 0.1% and 0.05%. Ocular hypertension was noted with 0.05% and 0.2%. No change in IOP was noted with 0.01% forskolin. The IOP lowering with 0.1% and 0.05% forskolin lasted approximately six hours. Mild, transient conjunctival chemosis was noted in the doses that decreased IOP. The contralateral control eye showed decreases in IOP, but the differences between control and tested eyes were significant by the Student's paired t test.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538408     DOI: 10.1001/archopht.1984.01040030124051

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  2 in total

1.  Dual-drug delivery system based on in situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efficacy.

Authors:  Saurabh Gupta; Malay K Samanta; Ashok M Raichur
Journal:  AAPS PharmSciTech       Date:  2010-02-25       Impact factor: 3.246

Review 2.  Neuroprotection in Glaucoma: Old and New Promising Treatments.

Authors:  Dario Rusciano; Salvatore Pezzino; Maria Giulia Mutolo; Rossella Giannotti; Aloisa Librando; Nicola Pescosolido
Journal:  Adv Pharmacol Sci       Date:  2017-10-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.